Chris Garabedian's Xontogeny shepherds two more companies through $60M Series A rounds

Katherine Lewin

News Reporter

Xontogeny CEO Chris Garabedian unveiled two rounds of Series A financing on Tuesday: one for Tellus Therapeutics, a neonatal care company, and another for Peroxitech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Chris Garabedian's Xontogeny shepherds two more companies through $60M Series A rounds

Katherine Lewin

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Exclusive: Day after GSK buyout, IDRx chair takes new investing role at Curie.Bio

#JPM25 live blog day 2: Pfizer's political positioning; The newest biopharmas to watch

Biohaven’s protein degrader is promising in early IgAN trial, heads straight to Phase 3

Daiichi Sankyo brings Glycotope antibody in-house for $132.5M

#JPM25 live blog day 1: How will Trump 2.0 impact the biopharma industry? Scott Gottlieb, Bob Nelsen share ...

Updated: J&J to buy Intra-Cellular for $14.6B in latest neuroscience bet

Chris Garabe­di­an's Xon­toge­ny shep­herds two more com­pa­nies through $60M Se­ries A rounds

News Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Chris Garabedian's Xontogeny shepherds two more companies through $60M Series A rounds